肿瘤相关抗原及其自身抗体在肝细胞癌早期诊断中的应用

王婷; 刘梅; 董蕾; 段钟平

doi:10.3969/j.issn.1001-5256.2016.07.047

肿瘤相关抗原及其自身抗体在肝细胞癌早期诊断中的应用

DOI: 10.3969/j.issn.1001-5256.2016.07.047

1. 首都医科大学附属北京佑安医院人工肝中心
2. 西安交通大学第二附属医院消化内科

基金项目:

首都医科大学基础-临床科研合作基金(15JL67)；北京卫生系统高技术人才培养项目基金(2015-3-104)；北京市教委科技计划面上项目(2015)；国家十二五科技重大专项“艾滋病和病毒性肝炎等重大传染病防治”(2012ZX10002004-006,2012ZX10004904-003-001,2013ZX10002002-006)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2034
- HTML全文浏览量: 12
- PDF下载量: 417
- 被引次数: 0
出版历程
- 出版日期: 2016-07-20

Application of tumor-associated antigens and their autoantibodies in early diagnosis of hepatocellular carcinoma

Research funding:

摘要

摘要: 肝细胞癌(HCC)的早期发现、早期诊断是提高HCC患者生存率的必要手段。研究发现,一种由肿瘤细胞释放的异常蛋白即肿瘤相关抗原刺激产生的自身抗体在HCC患者临床诊断前就已存在,因此可能成为HCC早期诊断的新型潜在标志物。简述了几种新型肿瘤相关抗原抗体在HCC诊断中的应用现状,认为肿瘤相关抗原抗体在HCC诊断中具有较大的前景及临床应用价值。
- 癌,肝细胞 /
- 抗原,肿瘤 /
- 抗体,肿瘤 /
- 早期诊断 /
- 综述
Abstract: Early identification and diagnosis of hepatocellular carcinoma( HCC) is necessary for improving survival rates of HCC patients.Studies have shown that the abnormal proteins released by tumor cells,i. e.,the autoantibodies stimulated by tumor- associated antigens( TAAs),can be detected before a clinical diagnosis of HCC is made,and therefore,such proteins may become the new markers for the early diagnosis of HCC. This article reviews the application of several new autoantibodies to tumor- associated antigens in the diagnosis of HCC and points out that these autoantibodies have promising prospects and clinical significance in the early diagnosis of HCC.
- carcinoma /
- hepatocellular /
- antigens /
- neoplasm /
- antibodies

HTML全文

参考文献(43)

[1]HONG Y,LONG J,LI H,et al.An analysis of immunoreactive signatures in early stage hepatocellular carcinoma[J].EBioM edicine,2015,2(5):438-446.

[2]POON D,ANDERSON BO,CHEN LT,et al.Management of hepatocellular carcinoma in Asia:consensus statement from the Asian Oncology Summit 2009[J].Lancet Oncol,2009,10(11):1111-1118.

[3]MASUZAKI R,KARP SJ,OMATA M.New serum markers of hepatocellular carcinoma[J].Semin Oncol,2012,39(4):434-439.

[4] CAVIGLIA GP,ABATE ML,PETRINI E,et al.Highly sensitive alpha-fetoprotein,Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection[J].Hepatol Res,2016,46(3):e130-e135.

[5] DAI M,CHEN X,LIU X,et al.Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma:a Meta-analysis[J].PLoS One,2015,10(10):e0140067.

[6]WANG L,YAO M,PAN LH,et al.Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma[J].Hepatobiliary Pancreat Dis Int,2015,14(4):361-366.

[7]EL-DIN BESSA SS,ELWAN NM,SULIMAN GA,et al.Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma[J].Arch Med Res,2010,41(7):541-547.

[8]GAO WF,ZHENG JS,SUN B.The clinical value of AFP in the diagnosis of hepatocellular carcinom[J].Curr Physician,2010,16(32):19-20.(in Chinese)高文峰,郑加生,孙斌.甲胎蛋白在原发性肝癌诊断中的临床价值[J].当代医学,2010,16(32):19-20.

[9]FARINATI F,MARINO D,DE GIORGIO M,et al.Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma:both or neither?[J].Am J Gastroenterol,2006,101(3):524-532.

[10]ERTLE JM,HEIDER D,WICHERT M,et al.A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma[J].Digestion,2013,87(2):121-131.

[11]TAN EM,ZHANG J.Autoantibodies to tumor-associated antigens:reporters from the immune system[J].Immunol Rev,2008,222:328-340.

[12]CASIANO CA,MEDIAVILLA-VARELA M,TAN EM.Tumor-associated antigen arrays for the serological diagnosis of cancer[J].Mol Cell Proteomics,2006,5(10):1745-1759.

[13]TAN HT,LOW J,LIM SG,et al.Serum autoantibodies as biomarkers for early cancer detection[J].FEBS J,2009,276(23):6880-6904.

[14] MADRID FF,MAROUN MC,OLIVERO OA,et al.Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis[J].BMC Cancer,2015,15:407.

[15]UMMANNI R,DUSCHARLA D,BARETT C,et al.Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers[J].J Proteomics,2015,119:218-229.

[16]HONG Y,HUANG J.Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma[J].World J Hepatol,2015,7(11):1581-1585.

[17]GADELHAK NA,GADELHAK SA,EL-MORSI DA,et al.Prognostic significance of three hepatitis markers(p53 antibodies,vascular endothelial growth factors and alpha fetoprotein)in patients with hepatocellular carcinoma[J].Hepatogastroenterology,2009,56(94-95):1417-1424.

[18] WANG Z,GOU W,LIU M,et al.Expression of P53 and HSP70 in chronic hepatitis,liver cirrhosis,and early and advanced hepatocellular carcinoma tissues and their diagnostic value in hepatocellular carcinoma:an immunohistochemical study[J].Med Sci Monit,2015,21:3209-3215.

[19] HM EI-E,GADELHAK SA,ABDELAZIZ MM,et al.Serum P53Abs in HCC patients with viral hepatitis-type C[J].Hepatogastroenterology,2014,61(134):1688-1695.

[20]LOOI K,MEGLIORINO R,SHI FD,et al.Humoral immune response to p16,a cyclin-dependent kinase inhibitor in human malignancies[J].Oncol Rep,2006,16(5):1105-1110.

[21]YUN JP,MIAO J,CHEN GG,et al.Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters[J].Br J Cancer,2007,96(3):477-484.

[22]LIU M,VARELA-RAMIREZ A,LI J,et al.Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma[J].Oncol Rep,2015,33(5):2245-2252.

[23]GOC A,ABDALLA M,AL-AZAYZIH A,et al.Rac1 activation driven by 14-3-3zeta dimerization promotes prostate cancer cellmatrix interactions,motility and transendothelial migration[J].PLoS One,2012,7(7):e40594.

[24]CHOI JE,HUR W,JUNG CK,et al.Silencing of 14-3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium[J].Cancer Lett,2011,303(2):99-107.

[25]NEAL CL,YAO J,YANG W,et al.14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival[J].Cancer Res,2009,69(8):3425-3432.

[26]LIU M,LIU X,REN P,et al.A cancer-related protein 14-3-3zeta is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma[J].Tumour Biol,2014,35(5):4247-4256.

[27]WANG HG,WU QY,ZHOU H,et al.The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians:a meta-analysis[J].Asian Pac J Cancer Prev,2014,15(13):5277-5281.

[28]YOSHIDA A,USHIKU T,MOTOI T,et al.MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma:correlation with a dedifferentiated subtype[J].Am J Surg Pathol,2012,36(3):423-431.

[29]HASHEMI M,OMRANI M,ESKANDARI-NASAB E,et al.A40-bp insertion/deletion polymorphism of Murine Double Minute2(MDM2)increased the risk of breast cancer in Zahedan,Southeast Iran[J].Iran Biomed J,2014,18(4):245-249.

[30]QIU M,LIU Y,YU X,et al.Interaction between p53 codon 72and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma[J].Tumour Biol,2016,37(3):3863-3870.

[31]LIU M,ZHENG SJ,CHEN Y,et al.Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma[J].J Immunol Res,2014,2014(1):906532.

[32]DAI L,REN P,LIU M,et al.Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma[J].Clin Immunol,2014,152(1-2):127-139.

[33]JIA X,GAO Y,ZHAI D,et al.Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma[J].Oncol Lett,2015,9(5):2347-2352.

[34]EZZELDIN M,BORREGO-DIAZ E,TAHA M,et al.RalA signaling pathway as a therapeutic target in hepatocellular carcinoma(HCC)[J].Mol Oncol,2014,8(5):1043-1053.

[35]WANG K,CHEN Y,LIU S,et al.Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma[J].Int J Immunopathol Pharmacol,2009,22(3):735-743.

[36]CHEN Y,ZHOU Y,QIU S,et al.Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma[J].Cancer Lett,2010,289(1):32-39.

[37]HUANG G,ZHOU Z,WANG H,et al.CAPER-alpha alternative splicing regulates the expression of vascular endothelial growth factor(1)(6)(5)in Ewing sarcoma cells[J].Cancer,2012,118(8):2106-2116.

[38]BELL JL,WACHTER K,MUHLECK B,et al.Insulin-like growth factor 2 mRNA-binding proteins(IGF2BPs):post-transcriptional drivers of cancer progression?[J].Cell Mol Life Sci,2013,70(15):2657-2675.

[39]ZHANG JY,CHAN EK,PENG XX,et al.A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma[J].J Exp Med,1999,189(7):1101-1110.

[40]GUTSCHNER T,HAMMERLE M,PAZAITIS N,et al.Insulin-like growth factor 2 mRNA-binding protein 1(IGF2BP1)is an important protumorigenic factor in hepatocellular carcinoma[J].Hepatology,2014,59(5):1900-1911.

[41]ZHANG JY,MEGLIORINO R,PENG XX,et al.Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma[J].J Hepatol,2007,46(1):107-114.

[42]MIDDLETON CH,IRVING W,ROBERTSON JF,et al.Serum autoantibody measurement for the detection of hepatocellular carcinoma[J].PLoS One,2014,9(8):e103867.

[43]ZHANG JY,TAN EM.Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors[J].Expert Rev Mol Diagn,2010,10(3):321-328.

施引文献

资源附件(0)

访问统计